| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 18,210 | 18,400 | ||
| General and administrative | 4,312 | 4,479 | ||
| Total operating expenses | 22,522 | 22,879 | ||
| Loss from operations | -22,522 | -22,879 | ||
| Interest income, net | 1,480 | 1,690 | ||
| Other (expense) income, net | -23 | -16 | ||
| Total other income | 1,457 | 1,674 | ||
| Loss before provision (benefit) for income taxes | -21,065 | -21,205 | ||
| Provision (benefit) for income taxes | -6 | 5 | ||
| Net loss | -21,059 | -21,210 | ||
| Unrealized gain (loss) on available for sale investments, net of tax | 69 | -61 | ||
| Foreign currency translation gain (loss) | 1 | -2 | ||
| Total other comprehensive income (loss) | 70 | - | ||
| Total comprehensive loss | -20,989 | -21,273 | ||
| Net loss per share - basic | -0.4 | -0.41 | ||
| Net loss per share - diluted | -0.4 | -0.41 | ||
| Weighted-average number of shares - basic | 52,993,238 | 52,010,827 | ||
| Weighted-average number of shares - diluted | 52,993,238 | 52,010,827 | ||
PMV Pharmaceuticals, Inc. (PMVP)
PMV Pharmaceuticals, Inc. (PMVP)